Maspin subcellular expression in wild-type and mutant TP53 gastric cancers

被引:13
|
作者
Gurzu, Simona [1 ,2 ]
Jung, Ioan [1 ]
Sugimura, Haruhiko [3 ]
Stefan-van Staden, Raluca Ioana [4 ]
Yamada, Hidetaka [3 ]
Natsume, Hiroko [3 ]
Iwashita, Yuji [3 ]
Szodorai, Rita [1 ]
Szederjesi, Janos [5 ]
机构
[1] George Emil Palade Univ Med Pharm Sci & Technol, Dept Pathol, Targu Mures 540139, Mures, Romania
[2] George Emil Palade Univ Med Pharm Sci & Technol, Res Ctr, Targu Mures 540139, Mures, Romania
[3] Hamamatsu Univ Sch Med, Dept Tumor Pathol, Hamamatsu, Shizuoka 4313192, Japan
[4] Natl Inst Res Electrochem & Condensed Matter, Bucharest 060021, Romania
[5] George Emil Palade Univ Med Pharm Sci & Technol, Intens Care Unit, Targu Mures 540139, Mures, Romania
关键词
p53; TP53; gene; Maspin; Gastric cancer; Carcinoma; COLORECTAL-CANCER; P53; SYSTEM;
D O I
10.4251/wjgo.v12.i7.741
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND Although the role of p53 in the evolution and prognosis of gastric cancer (GC) has been extensively examined, the exact mechanism of action is incompletely understood. In the last years, p53-target genes were supposed to be involved in the p53 pathway. One of them is the tumor-suppressor gene Maspin, which codifies the protein with the same name. Maspin activity depends on its subcellular localization. To our knowledge, the possible role ofTP53gene in Maspin subcellular localization, in GC cells, has not yet been studied in a large number of human samples. AIM To evaluate the possible role of wild-type and mutated p53 in Maspin subcellular localization. METHODS The present study included 266 consecutive patients with GC in whichTP53gene status, and mutations in exons 2 to 11, respectively, were analyzed and correlated with immunohistochemical expression of p53 and Maspin. RESULTS None of the 266 cases showed mutations in exon 9. The rate ofTP53mutations was 33.83%. The mutation rate was slightly higher in distally-located GCs, with a lower degree (<= 5 buds/ high power fields) of dyscohesivity (P< 0.01). The wild-type cases had a longer survival, compared with mutant GCs, especially in patients without lymph node metastases, despite the high depth of tumor infiltration (P= 0.01). The Dukes-MAC-like staging system was proved to have the most significant independent prognostic value (P< 0.01). The statistical correlations proved thatTP53gene mutations in exon 7 might induce knockdown of Maspin, but wild-type p53 can partially restore nuclear Maspin expression and decrease the metastatic potential of gastric adenocarcinoma cells. CONCLUSION Downregulated Maspin might be induced by mutations in exon 7 of theTP53gene but wild-type p53 can partially restore nuclear Maspin expression. These findings should be proved in experimental studies.
引用
收藏
页码:741 / 755
页数:15
相关论文
共 50 条
  • [31] Clinical Significance of PICT1 in Patients of Hepatocellular Carcinoma with Wild-Type TP53
    Masahisa Ishibashi
    Ryunosuke Kogo
    Kohei Shibata
    Hiroki Ueo
    Ryutaro Uchi
    Tae Matsumura
    Yuki Takano
    Genta Sawada
    Yusuke Takahashi
    Kousuke Mima
    Junji Kurashige
    Sayuri Akiyoshi
    Takeshi Iwaya
    Hidetoshi Eguchi
    Tomoya Sudo
    Keishi Sugimachi
    Akira Suzuki
    Go Wakabayashi
    Masaki Mori
    Koshi Mimori
    Annals of Surgical Oncology, 2013, 20 : 537 - 544
  • [32] Clinical Significance of PICT1 in Patients of Hepatocellular Carcinoma with Wild-Type TP53
    Ishibashi, Masahisa
    Kogo, Ryunosuke
    Shibata, Kohei
    Ueo, Hiroki
    Uchi, Ryutaro
    Matsumura, Tae
    Takano, Yuki
    Sawada, Genta
    Takahashi, Yusuke
    Mima, Kousuke
    Kurashige, Junji
    Akiyoshi, Sayuri
    Iwaya, Takeshi
    Eguchi, Hidetoshi
    Sudo, Tomoya
    Sugimachi, Keishi
    Suzuki, Akira
    Wakabayashi, Go
    Mori, Masaki
    Mimori, Koshi
    ANNALS OF SURGICAL ONCOLOGY, 2013, 20 : S537 - S544
  • [33] Expression signature based on TP53 target genes doesn't predict response to TP53-MDM2 inhibitor in wild type TP53 tumors
    Sonkin, Dmitriy
    ELIFE, 2015, 4
  • [34] Expression signatures of TP53 mutations in serous ovarian cancers
    Marcus Q Bernardini
    Tsukasa Baba
    Paula S Lee
    Jason C Barnett
    Gregory P Sfakianos
    Angeles Alvarez Secord
    Susan K Murphy
    Edwin Iversen
    Jeffrey R Marks
    Andrew Berchuck
    BMC Cancer, 10
  • [35] Expression signatures of TP53 mutations in serous ovarian cancers
    Bernardini, Marcus Q.
    Baba, Tsukasa
    Lee, Paula S.
    Barnett, Jason C.
    Sfakianos, Gregory P.
    Secord, Angeles Alvarez
    Murphy, Susan K.
    Iversen, Edwin
    Marks, Jeffrey R.
    Berchuck, Andrew
    BMC CANCER, 2010, 10 : 237
  • [36] TP53 mutations, expression and interaction networks in human cancers
    Wang, Xiaosheng
    Sun, Qingrong
    ONCOTARGET, 2017, 8 (01) : 624 - 643
  • [37] Allele-specific wild-type TP53 expression in the unaffected carrier parent of children with Li-Fraumeni syndrome
    Buzby, Jeffrey S.
    Williams, Shirley A.
    Schaffer, Lana
    Head, Steven R.
    Nugent, Diane J.
    CANCER GENETICS, 2017, 211 : 9 - 17
  • [38] Low ATM Expression Levels Predict Resistance to Anthracyclins in TP53 and CHK2 Wild-Type Breast Tumors
    Knappskog, S.
    Chrisanthar, R.
    Lokkevik, E.
    Anker, G.
    Ostenstad, B.
    Lundgren, S.
    Risberg, T.
    Mjaaland, I.
    Staalesen, V.
    Miletic, H.
    Leirvaag, B.
    Lillehaug, J. R.
    Lonning, P. E.
    CANCER RESEARCH, 2010, 70
  • [39] COTRANSLATION OF ACTIVATED MUTANT P53 WITH WILD-TYPE DRIVES THE WILD-TYPE P53 PROTEIN INTO THE MUTANT CONFORMATION
    MILNER, J
    MEDCALF, EA
    CELL, 1991, 65 (05) : 765 - 774
  • [40] Case Report: A novel TP53 mutation in a patient with quadruple wild-type gastrointestinal stromal tumor
    Chen, Yuhong
    Chen, Junyong
    Long, Liansheng
    Han, Leng
    Mi, Xiaohui
    Song, Yanfang
    Cheng, Huanqing
    Zhang, Yanrui
    Cheng, Liyang
    FRONTIERS IN ONCOLOGY, 2023, 13